JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34(+) cells in vitro and in vivo

Chronic myeloid leukemia (CML) stem cell survival is not dependent on BCR-ABL protein kinase and treatment with ABL tyrosine kinase inhibitors cures only a minority of CML patients, thus highlighting the need for novel therapeutic targets. The Janus kinase (JAK)2/signal transducer and activator of t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Gallipoli, Paolo, Cook, Amy, Rhodes, Susan, Hopcroft, Lisa, Wheadon, Helen, Whetton, Anthony D., Jørgensen, Heather G., Bhatia, Ravi, Holyoake, Tessa L.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2014
Matèries:
Myeloid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4148771/
https://ncbi.nlm.nih.gov/pubmed/24957147
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-12-545640
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars